Enstone Ashley, Greaney Maire, Povsic Manca, Wyn Robin, Penrod John R, Yuan Yong
Adelphi Values, Adelphi Mill, Bollington, Cheshire, UK.
Bristol-Myers Squibb, Princeton, NJ, USA.
Pharmacoecon Open. 2018 Jun;2(2):125-139. doi: 10.1007/s41669-017-0045-0.
Small cell lung cancer (SCLC), the most aggressive form of lung carcinoma, represents approximately 15% of all lung cancers; however, the economic and healthcare burden of SCLC is not well-defined.
The aim of this study was to explore the impact of SCLC on healthcare costs through a systematic literature review (SLR).
Using the OVID search engine, the SLR was conducted in PubMed, MEDLINE In-Process, EMBASE, EconLIT and the National Health Service Economic Evaluation Database (NHS EED). Searches were limited to studies published between January 2005 and 24 February 2016, and excluded preclinical studies. Additional internet-based searches were conducted. In total, 229 abstracts were retrieved and systematically screened for eligibility, with 17 publications retained.
The majority of publications provided data on limited and extensive disease of SCLC. The reported burden was categorised as direct costs and indirect costs, with the majority of the publications (n = 16) reporting on direct costs and one reporting on both direct and indirect costs. The only indirect costs reported for SCLC were lost productivity (premature mortality costs) and caregiver burden. Chemotherapy, diagnostic costs and treatment costs were identified as significant costs when managing SCLC patients, including the associated treatment costs such as hospitalisation, nurse visits, emergency room visits, follow-up appointments and outpatient care.
SCLC and its treatment have a substantial impact on costs. The scarcity and heterogeneity of economic cost data negated meaningful cost comparison, highlighting the need for further research. Capturing the economic burden of SCLC may help patients and clinicians make informed treatment choices and improve SCLC management.
小细胞肺癌（SCLC）是肺癌中侵袭性最强的类型，约占所有肺癌的15%；然而，SCLC的经济和医疗负担尚不明确。
本研究旨在通过系统文献综述（SLR）探讨SCLC对医疗成本的影响。
使用OVID搜索引擎，在PubMed、MEDLINE在研数据库、EMBASE、EconLIT和国家卫生服务经济评估数据库（NHS EED）中进行SLR。搜索仅限于2005年1月至2016年2月24日发表的研究，并排除临床前研究。还进行了额外的基于互联网的搜索。总共检索到229篇摘要，并对其进行系统筛选以确定是否符合条件，最终保留了17篇出版物。
大多数出版物提供了SCLC局限性和广泛性疾病的数据。报告的负担分为直接成本和间接成本，大多数出版物（n = 16）报告了直接成本，一篇报告了直接成本和间接成本。SCLC报告的唯一间接成本是生产力损失（过早死亡成本）和护理负担。化疗、诊断成本和治疗成本被确定为管理SCLC患者时的重大成本，包括相关的治疗成本，如住院、护士探访、急诊室就诊、随访预约和门诊护理。
SCLC及其治疗对成本有重大影响。经济成本数据的稀缺性和异质性否定了有意义的成本比较，凸显了进一步研究的必要性。了解SCLC的经济负担可能有助于患者和临床医生做出明智的治疗选择并改善SCLC的管理。
